ArticleChina CDC weekly2023
SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023.
Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.Journal of virology · 2026Article
- A Human Mobility-Based Modeling Study of Influenza Vaccination Strategies Across Socioeconomically Disparate Regions in China.Vaccines · 2026Article
- Shifting seasonal patterns of influenza before, during, and after the COVID-19 pandemic in Shanghai, China: A population-based surveillance study, 2015-2023.Biosafety and health · 2026Article
- Persistent glycemic deterioration after the COVID-19 pandemic: A large cohort analysis stratifying by care settings, specialties, and gender disparities in Chengdu, China.Preventive medicine reports · 2026Article
- Divergent surveillance needs and resource allocation for COVID-19 and influenza: insights from a community-based syndromic surveillance study in Shanghai (2024-2025).Frontiers in public health · 2026Article
- Article
- China's post-zero-COVID Omicron wave: A Bayesian analysis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Genetic characteristics of influenza A/H3N2 virus in Jiaxing, China (2019-2024).Virology journal · 2025Article
- Genetic characteristics analysis of influenza A(H1N1) virus in Jiaxing, China, in the postepidemic era.BMC infectious diseases · 2025Article
- The Clinical and Metabolic Profiles in Menstrual Changes Among Reproductive-Aged Women Post-COVID-19.MedComm · 2025Article
- Predicting influenza in China from October 1, 2023, to February 5, 2024: A transmission dynamics model based on population migration.Infectious Disease Modelling · 2025Article
- A Clinical Risk Score Based on Albumin and Electrolyte Levels for Predicting Death Risk in Hospitalized Elderly COVID-19 Patients.International journal of general medicine · 2025Article
- Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19.Current medicinal chemistry · 2025Article
- Gender differences in the prevalence and correlates of COVID-19 fear among mental health professionals: a network perspective based on a national survey in China.Frontiers in psychiatry · 2025Article
- Fever duration, peak temperature and associated symptoms in Chinese adults with SARS-CoV-2 infection: a cross-sectional study.Frontiers in medicine · 2025Article
- Surveillance of Pathogens Causing Viral Diarrhea in Yichang in 2022 and 2023.Intervirology · 2025Article
- Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study.Human vaccines & immunotherapeutics · 2024Article
- Two Peaks of Seasonal Influenza Epidemics - China, 2023.China CDC weekly · 2024Article
- Article
- Vaccines reduced hospital length of stay and fraction of inspired oxygen of COVID-19 patients: A retrospective cohort study.Preventive medicine reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The World Health Organization (WHO) proposed using influenza surveillance systems to carry out coronavirus disease 2019 (COVID-19) surveillance due to the similarity between the two diseases in some respiratory symptoms. To assess the prevalence of COVID-19, we analyzed the influenza-like illness (ILI) and positive rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detections in ILI patients reported to the influenza Surveillance Information System (CNISIS) since late 2022. Methods: Data related to ILI were reported by national surveillance sentinel hospitals. Positive testing for SARS-CoV-2 and influenza viruses was conducted using real-time reverse transcription polymerase chain reaction (rRT-PCR) detection by the national influenza surveillance network laboratories. Surveillance data were reported to CNISIS. Results: Beginning on December 12, 2022 (Week 50), the ILI percentage increased dramatically, peaking in Week 51 at 12.1%. Subsequently, the ILI percentage began to decline rapidly from Week 52, 2022, and by Week 6, 2023 (February 6-12), the ILI and ILI percentage had returned to the levels observed at the beginning of December 2022. From December 1, 2022 to February 12, 2023, 115,844 specimens were tested for both SARS-CoV-2 and influenza virus. Of these, 30,381 (26.2%) were positive for SARS-CoV-2 and 1,763 (1.5%) were positive for influenza virus. The positive rate of SARS-CoV-2 tests peaked at 74.1% around December 23 and 25. Conclusions: Sentinel-based surveillance, previously established for influenza, is an effective way to track the circulation trend of SARS-CoV-2 during community-level epidemics. There was no co-prevalence of SARS-CoV-2 and influenza virus during the outbreak of SARS-CoV-2, even during the winter influenza season. However, it is important to remain vigilant for the potential rise of influenza activities following the COVID-19 epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.